Clinical Trials Logo

Sleep Wake Disorders clinical trials

View clinical trials related to Sleep Wake Disorders.

Filter by:

NCT ID: NCT01142258 Completed - Alzheimer's Disease Clinical Trials

Trazodone for Sleep Disorders in Alzheimer's Disease

Start date: March 2010
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine whether trazodone is effective in the treatment of sleep disorders in Alzheimer's disease (AD).

NCT ID: NCT01122849 Completed - Sleep Disorders Clinical Trials

Exploratory Subjective Sleep Study of a Prototype Nasal Dilator

Start date: October 1, 2009
Phase: Phase 2
Study type: Interventional

The purpose of this exploratory study is to evaluate the subjective measures of congestion and sleep quality in subjects who suffer from chronic nasal congestion and report trouble with their sleep.

NCT ID: NCT01030939 Completed - Sleep Disorders Clinical Trials

Study to Investigate Safety, Tolerability, Pharmacokinetics and Cardiac Function After Repeat Doses of SB-649868 in Healthy-volunteers

Start date: August 27, 2009
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine whether SB-649868 is safe, tolerable after repeated administrations in adult and elderly healthy volunteers. Pharmacokinetics and effects on cardiac function of repeated doses are studied

NCT ID: NCT01014533 Completed - Insomnia Clinical Trials

Pharmacotherapy and Mechanisms of Sleep Disturbance in Alcohol Dependence

MA
Start date: May 2007
Phase: N/A
Study type: Interventional

Insomnia and other sleep abnormalities are common, persistent, and associated with relapse in alcohol-dependent patients. The overall, long-term objectives of the proposed research are to investigate the neurophysiologic mechanisms of sleep disturbance that are associated with relapse in patients with alcohol dependence, and to target those mechanisms with medication in order to reduce relapse risk. The specific research aims are: 1. To investigate three potential mechanisms of sleep disturbance in alcoholic patients: impaired sleep drive, impaired circadian regulation of alertness, and brain hyperactivation; 2. To investigate short-term effects of medication on sleep and its regulatory mechanisms in alcoholics; 3. To investigate the short-term clinical course of alcoholism as a function of baseline sleep parameters. In Study Phases I & II (Screening & Baseline: 10+ days), subjects are assessed to diagnose alcohol dependence, determine baseline values for drinking and sleeping, and rule out confounding sleep-impairing causes. Phase III (Medication: 10 days), is a randomized, double-blind parallel design comparison of gabapentin vs. placebo on mechanisms of sleep. It is not a therapeutic or clinical trial. Phases II & III each have 7 days of monitoring sleep and activity, followed by 3 nights in the University of Michigan (UM) sleep laboratory to assess all-night EEG activity and Dim-Light Melatonin Onset (DLMO), a measure of circadian rhythm. Phase IV is a 2-day medication taper and Phase V (Follow-up) consists of one visit or telephone call after 12 weeks to assess course of drinking. In summary, sleep disturbance in alcoholic patients increases their risk of relapse. This study proposes to investigate the mechanisms causing sleep disturbance in alcoholics and to determine if those mechanisms predict return to drinking after 12 weeks. Relevance: Alcoholism is a devastating chronic disorder that in any one year affects 10% of adults, costs over $185 billion, and causes more than 100,000 deaths in the U.S. Despite treatment, most alcoholic patients achieve only short-term abstinence. Medically-based treatment improvements are needed that target neurophysiologic mechanisms of relapse. Overall public health will be improved by developing science-based treatments that can augment existing, but only partially effective, treatment approaches.

NCT ID: NCT00994279 Completed - Breast Cancer Clinical Trials

Yoga or Educational Wellness Class for Women With Stage I, Stage II, or Stage III Breast Cancer Undergoing Chemotherapy

Start date: January 2010
Phase: N/A
Study type: Interventional

RATIONALE: Yoga and wellness classes may reduce fatigue and improve mood, sleep, and quality of life in women receiving chemotherapy for breast cancer. It is not yet known whether yoga is more effective than wellness education for women with breast cancer who are undergoing chemotherapy. PURPOSE: This randomized phase II trial is studying a community-based yoga class to see how well it works compared with an educational wellness class for women with stage I, stage II, or stage III breast cancer undergoing chemotherapy.

NCT ID: NCT00992160 Completed - Sleep Disorders Clinical Trials

Vestipitant 28-day Tolerance Study

Start date: May 2009
Phase: Phase 2
Study type: Interventional

This study is a 28-day polysomnographic and subjective assessment of oral Vestipitant 15mg/day for treatment of Primary Insomnia in adults outpatients.

NCT ID: NCT00990106 Completed - Clinical trials for Stress Disorders, Post-Traumatic

Augmentation Trial of Prazosin for Post-Traumatic Stress Disorder (PTSD)

Start date: September 2009
Phase: N/A
Study type: Interventional

The purpose of this study is to determine whether prazosin will: - reduce the incidence of nightmares and sleep disturbance - increase functioning and sense of well being in combat-trauma exposed Operation Iraqi Freedom/Operation Enduring Freedom (OIF/OEF) Veterans.

NCT ID: NCT00988104 Completed - Clinical trials for Stress Disorders, Post-Traumatic

Preventing Long Term Psychiatric Disability Among Those With Major Burn Injuries

SMART
Start date: October 16, 2007
Phase: N/A
Study type: Interventional

The purpose of this study is to determine whether a newly developed, brief cognitive behavioral intervention, relative to supportive counseling, is effective in reducing acute stress disorder (ASD) and preventing post traumatic stress disorder (PTSD) and depression.

NCT ID: NCT00940589 Completed - Alzheimer's Disease Clinical Trials

Efficacy of Circadin® 2 mg in Patients With Mild to Moderate Alzheimer Disease Treated With AChE Inhibitor

Start date: September 2009
Phase: Phase 2
Study type: Interventional

The aim of this exploratory randomized, placebo controlled study is to evaluate the efficacy of Circadin® 2mg in patients with mild to moderate Alzheimer Disease (AD) treated with the acetylcholinesterase (AChE) inhibitor. The effects of add-on Circadin® 2mg vs. placebo on the decline in cognitive skills and global functioning, as well as on daytime somnolence and will be assessed.

NCT ID: NCT00895375 Completed - Psoriasis Clinical Trials

Prevalence of Sleep Disturbances in Psoriasis

Start date: October 2009
Phase:
Study type: Observational

The purpose of this study is to compare the sleep quality of patients with psoriasis to patients without psoriasis.